Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 87 | 2024 | 5314 | 8.110 |
Why?
|
Lung Neoplasms | 101 | 2024 | 13381 | 6.310 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 16 | 2024 | 1745 | 2.270 |
Why?
|
Immunotherapy | 24 | 2024 | 4652 | 1.960 |
Why?
|
Mutation | 37 | 2024 | 30053 | 1.170 |
Why?
|
Antineoplastic Agents | 18 | 2023 | 13642 | 1.130 |
Why?
|
Gene Rearrangement | 6 | 2024 | 1125 | 1.070 |
Why?
|
Drug Resistance, Neoplasm | 12 | 2024 | 5305 | 1.020 |
Why?
|
Protein-Tyrosine Kinases | 6 | 2024 | 2425 | 0.810 |
Why?
|
Protein Kinase Inhibitors | 15 | 2024 | 5672 | 0.810 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2024 | 1609 | 0.800 |
Why?
|
Neoplasms | 16 | 2024 | 22173 | 0.780 |
Why?
|
NF-E2-Related Factor 2 | 7 | 2024 | 373 | 0.680 |
Why?
|
Molecular Targeted Therapy | 8 | 2020 | 2811 | 0.640 |
Why?
|
Proto-Oncogene Proteins | 7 | 2024 | 4514 | 0.630 |
Why?
|
DNA Repair Enzymes | 1 | 2020 | 346 | 0.610 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2018 | 117 | 0.600 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 11742 | 0.600 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2020 | 4024 | 0.580 |
Why?
|
Neovascularization, Pathologic | 2 | 2017 | 2645 | 0.570 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2017 | 186 | 0.560 |
Why?
|
Enzyme Inhibitors | 2 | 2017 | 3713 | 0.560 |
Why?
|
Solitary Fibrous Tumor, Pleural | 1 | 2016 | 25 | 0.550 |
Why?
|
Receptor, trkB | 1 | 2017 | 124 | 0.530 |
Why?
|
Immunoconjugates | 2 | 2023 | 953 | 0.520 |
Why?
|
Aortic Arch Syndromes | 1 | 2015 | 19 | 0.520 |
Why?
|
Colitis, Ischemic | 1 | 2015 | 32 | 0.500 |
Why?
|
Humans | 126 | 2024 | 761596 | 0.500 |
Why?
|
Aged, 80 and over | 32 | 2024 | 58984 | 0.490 |
Why?
|
Receptor Protein-Tyrosine Kinases | 5 | 2018 | 1626 | 0.480 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2024 | 571 | 0.480 |
Why?
|
Prednisone | 1 | 2019 | 1563 | 0.470 |
Why?
|
Melanosis | 1 | 2015 | 93 | 0.460 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 423 | 0.460 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2021 | 3639 | 0.440 |
Why?
|
DNA Mutational Analysis | 2 | 2020 | 4111 | 0.430 |
Why?
|
Pyrazoles | 3 | 2018 | 2009 | 0.380 |
Why?
|
Aged | 46 | 2024 | 169310 | 0.370 |
Why?
|
Central Nervous System Neoplasms | 2 | 2016 | 916 | 0.370 |
Why?
|
Retrospective Studies | 39 | 2024 | 80647 | 0.360 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 1881 | 0.350 |
Why?
|
Survival Rate | 11 | 2021 | 12723 | 0.350 |
Why?
|
Adenocarcinoma | 3 | 2018 | 6345 | 0.330 |
Why?
|
Aorta, Thoracic | 1 | 2015 | 1096 | 0.330 |
Why?
|
Middle Aged | 43 | 2024 | 220921 | 0.320 |
Why?
|
Female | 57 | 2024 | 392705 | 0.310 |
Why?
|
Drug Delivery Systems | 1 | 2019 | 2226 | 0.310 |
Why?
|
Nanoparticles | 1 | 2019 | 1958 | 0.300 |
Why?
|
Genomics | 8 | 2024 | 5821 | 0.290 |
Why?
|
Antibodies, Monoclonal | 5 | 2024 | 9177 | 0.290 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2048 | 0.290 |
Why?
|
Pyridines | 2 | 2024 | 2875 | 0.290 |
Why?
|
Piperazines | 2 | 2024 | 2523 | 0.280 |
Why?
|
Male | 53 | 2024 | 360846 | 0.280 |
Why?
|
Liver Neoplasms | 1 | 2023 | 4317 | 0.280 |
Why?
|
Prognosis | 16 | 2024 | 29629 | 0.280 |
Why?
|
Membrane Glycoproteins | 1 | 2017 | 3701 | 0.260 |
Why?
|
Acrylamides | 2 | 2019 | 260 | 0.260 |
Why?
|
Disease Progression | 6 | 2021 | 13510 | 0.260 |
Why?
|
Carbazoles | 2 | 2018 | 220 | 0.250 |
Why?
|
Proto-Oncogene Proteins c-ret | 2 | 2024 | 225 | 0.250 |
Why?
|
Survival Analysis | 6 | 2020 | 10090 | 0.250 |
Why?
|
Aniline Compounds | 3 | 2023 | 1069 | 0.240 |
Why?
|
Adult | 30 | 2024 | 221210 | 0.230 |
Why?
|
Pneumonia | 3 | 2023 | 2143 | 0.230 |
Why?
|
Palliative Care | 1 | 2019 | 3598 | 0.230 |
Why?
|
Neoplasm Metastasis | 4 | 2019 | 4915 | 0.230 |
Why?
|
Exons | 2 | 2020 | 2391 | 0.210 |
Why?
|
Thyroid Neoplasms | 1 | 2016 | 2332 | 0.210 |
Why?
|
Indazoles | 1 | 2024 | 304 | 0.210 |
Why?
|
Cholesterol, HDL | 2 | 2018 | 1814 | 0.200 |
Why?
|
Point Mutation | 2 | 2024 | 1595 | 0.190 |
Why?
|
Disease-Free Survival | 4 | 2019 | 6815 | 0.190 |
Why?
|
DNA Repair | 2 | 2020 | 2046 | 0.180 |
Why?
|
Colitis | 2 | 2019 | 1233 | 0.180 |
Why?
|
Neoplasm Staging | 7 | 2021 | 11120 | 0.180 |
Why?
|
Treatment Outcome | 14 | 2022 | 64685 | 0.180 |
Why?
|
Thyroiditis | 1 | 2020 | 86 | 0.180 |
Why?
|
DNA Damage | 2 | 2020 | 2449 | 0.170 |
Why?
|
Platinum | 2 | 2019 | 220 | 0.170 |
Why?
|
Follow-Up Studies | 10 | 2020 | 39106 | 0.170 |
Why?
|
Toll-Like Receptor 7 | 1 | 2021 | 177 | 0.170 |
Why?
|
Phospholipase D | 1 | 2019 | 67 | 0.170 |
Why?
|
Radioimmunotherapy | 1 | 2019 | 91 | 0.170 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2024 | 774 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 641 | 0.160 |
Why?
|
Thoracic Neoplasms | 1 | 2021 | 267 | 0.160 |
Why?
|
Body Mass Index | 4 | 2022 | 12953 | 0.160 |
Why?
|
Immunophenotyping | 1 | 2024 | 1869 | 0.160 |
Why?
|
Benzamides | 1 | 2024 | 1371 | 0.160 |
Why?
|
Radiation Pneumonitis | 1 | 2019 | 102 | 0.160 |
Why?
|
Translocation, Genetic | 1 | 2024 | 1393 | 0.150 |
Why?
|
Piperidines | 2 | 2018 | 1656 | 0.150 |
Why?
|
Withholding Treatment | 2 | 2020 | 617 | 0.150 |
Why?
|
Protein-Lysine 6-Oxidase | 1 | 2017 | 55 | 0.150 |
Why?
|
Brain Neoplasms | 5 | 2023 | 9032 | 0.150 |
Why?
|
Ligands | 2 | 2021 | 3272 | 0.140 |
Why?
|
Protein Isoforms | 1 | 2022 | 1699 | 0.140 |
Why?
|
DNA Helicases | 4 | 2023 | 851 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2024 | 8554 | 0.140 |
Why?
|
Genes, Tumor Suppressor | 2 | 2024 | 1062 | 0.140 |
Why?
|
Lactams, Macrocyclic | 1 | 2018 | 318 | 0.140 |
Why?
|
Immune System Diseases | 1 | 2019 | 256 | 0.130 |
Why?
|
Glucuronidase | 1 | 2017 | 202 | 0.130 |
Why?
|
Animals | 14 | 2024 | 168475 | 0.130 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2017 | 362 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2021 | 1186 | 0.130 |
Why?
|
Tumor Escape | 1 | 2018 | 370 | 0.130 |
Why?
|
Young Adult | 9 | 2022 | 59260 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2017 | 339 | 0.130 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1616 | 0.120 |
Why?
|
Thoracotomy | 1 | 2016 | 367 | 0.120 |
Why?
|
Body Composition | 1 | 2024 | 2426 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2024 | 2057 | 0.120 |
Why?
|
Smoking | 2 | 2021 | 9053 | 0.120 |
Why?
|
Hepatitis B | 1 | 2020 | 705 | 0.120 |
Why?
|
Lipoproteins, HDL | 1 | 2018 | 676 | 0.110 |
Why?
|
Mutation, Missense | 1 | 2023 | 2571 | 0.110 |
Why?
|
Colonic Diseases | 1 | 2015 | 201 | 0.110 |
Why?
|
Immune System | 1 | 2019 | 796 | 0.110 |
Why?
|
Tumor Microenvironment | 5 | 2024 | 3878 | 0.110 |
Why?
|
Lymphocytes | 1 | 2021 | 2612 | 0.110 |
Why?
|
Italy | 3 | 2019 | 842 | 0.110 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6484 | 0.110 |
Why?
|
Alleles | 1 | 2024 | 6864 | 0.110 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2017 | 1171 | 0.100 |
Why?
|
Remission Induction | 1 | 2018 | 2397 | 0.100 |
Why?
|
Delayed Diagnosis | 1 | 2015 | 463 | 0.100 |
Why?
|
Thyroidectomy | 1 | 2016 | 908 | 0.090 |
Why?
|
Incidental Findings | 1 | 2015 | 697 | 0.090 |
Why?
|
Interleukin-6 | 1 | 2020 | 3208 | 0.090 |
Why?
|
Pyrimidines | 2 | 2024 | 3028 | 0.080 |
Why?
|
Aneuploidy | 2 | 2023 | 552 | 0.080 |
Why?
|
Hepatitis C | 1 | 2020 | 1584 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2018 | 2302 | 0.080 |
Why?
|
Obesity | 3 | 2020 | 12947 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3767 | 0.080 |
Why?
|
Cohort Studies | 5 | 2023 | 41495 | 0.080 |
Why?
|
Regeneration | 1 | 2017 | 1512 | 0.080 |
Why?
|
ras Proteins | 1 | 2013 | 1054 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2019 | 5247 | 0.070 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4740 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10194 | 0.070 |
Why?
|
Time Factors | 2 | 2021 | 39969 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12463 | 0.070 |
Why?
|
Dyspnea | 1 | 2015 | 1347 | 0.070 |
Why?
|
Cell Line, Tumor | 4 | 2024 | 16990 | 0.070 |
Why?
|
Nuclear Proteins | 4 | 2023 | 5799 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2321 | 0.070 |
Why?
|
Incidence | 6 | 2023 | 21355 | 0.070 |
Why?
|
Prospective Studies | 6 | 2024 | 54423 | 0.070 |
Why?
|
Respiratory Insufficiency | 1 | 2015 | 1230 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2244 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 1866 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3605 | 0.060 |
Why?
|
Radiography | 1 | 2016 | 6965 | 0.060 |
Why?
|
Decision Making | 1 | 2019 | 3929 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20568 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2019 | 2422 | 0.060 |
Why?
|
Acetonitriles | 1 | 2024 | 54 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15266 | 0.060 |
Why?
|
Stem Cells | 1 | 2017 | 3524 | 0.060 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3204 | 0.060 |
Why?
|
Bayes Theorem | 2 | 2022 | 2330 | 0.060 |
Why?
|
Guanosine Triphosphate | 1 | 2024 | 316 | 0.060 |
Why?
|
Lipid Peroxidation | 1 | 2024 | 271 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12690 | 0.050 |
Why?
|
Receptor, trkA | 1 | 2024 | 159 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2024 | 2917 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2024 | 517 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11076 | 0.050 |
Why?
|
Oximes | 1 | 2024 | 303 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7406 | 0.050 |
Why?
|
Transcription Factors | 4 | 2023 | 12130 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6484 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 143 | 0.050 |
Why?
|
Pyrimidinones | 1 | 2024 | 385 | 0.050 |
Why?
|
Lung | 1 | 2020 | 10002 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 8527 | 0.050 |
Why?
|
Sucrose | 1 | 2021 | 158 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 857 | 0.040 |
Why?
|
Loss of Heterozygosity | 1 | 2022 | 662 | 0.040 |
Why?
|
Mice | 5 | 2024 | 81539 | 0.040 |
Why?
|
Chromosomes | 1 | 2023 | 578 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12973 | 0.040 |
Why?
|
Signal Transduction | 2 | 2024 | 23447 | 0.040 |
Why?
|
Pyridones | 1 | 2024 | 809 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 634 | 0.040 |
Why?
|
Imidazoles | 1 | 2024 | 1180 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9280 | 0.040 |
Why?
|
Lactams | 1 | 2018 | 156 | 0.040 |
Why?
|
Cell Death | 1 | 2023 | 1679 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 1092 | 0.030 |
Why?
|
Chromosome Aberrations | 1 | 2023 | 1768 | 0.030 |
Why?
|
Causality | 1 | 2021 | 1242 | 0.030 |
Why?
|
Oncogenes | 1 | 2021 | 1222 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1892 | 0.030 |
Why?
|
Cardiovascular Diseases | 2 | 2018 | 15502 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1380 | 0.030 |
Why?
|
Aminopyridines | 1 | 2018 | 573 | 0.030 |
Why?
|
HIV Infections | 1 | 2021 | 17354 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2805 | 0.030 |
Why?
|
Apoptosis | 2 | 2020 | 9490 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2023 | 2865 | 0.030 |
Why?
|
Hypolipidemic Agents | 1 | 2018 | 609 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2024 | 3113 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1590 | 0.030 |
Why?
|
Brain | 2 | 2016 | 27121 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2016 | 36426 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15843 | 0.020 |
Why?
|
Disease Management | 1 | 2021 | 2508 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4580 | 0.020 |
Why?
|
Recombination, Genetic | 1 | 2015 | 1519 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2018 | 1902 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2643 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3384 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3617 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2015 | 2510 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8633 | 0.020 |
Why?
|
Risk Factors | 3 | 2020 | 74213 | 0.020 |
Why?
|
Overweight | 1 | 2019 | 2417 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4244 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15733 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12990 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16592 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6992 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8002 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4016 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10774 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 17904 | 0.010 |
Why?
|
Algorithms | 1 | 2023 | 14033 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10721 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26129 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23996 | 0.010 |
Why?
|